KDR and glioblastoma: For example, a phase II clinical trial (NCT00035656) demonstrated that cediranib, a potent VEGFR inhibitor targeting VEGFR-1, VEGFR-2, and VEGFR-3, promoted vessel normalization and improved blood flow in patients with glioblastoma (173).